The umbrella term “Digital health” tries to capture the complexity and the diversity of a constantly and incredibly rapidly evolving technological landscape that is embracing and revolutionising healthcare. From the application of AI across the entire pharmaceutical value chain (think drug discovery, clinical trial accrual, analysis of RWE and many more!), to the development of apps for patient monitoring and the establishment of telemedicine platforms, Eradigm has been supporting our pharma partners to understand this industry-changing trend aiming to define the best strategies to adopt it and bring value to patients, physicians and payers.
Our specialist team has been applying the digital lens across therapeutic areas such as oncology, cardiovascular, rare disease, immunology, with capabilities including (but not limited to!):
- Deep assessment of the digital therapeutic (DTx) landscape and analysis of big pharma development & acquisition strategy.
- Global market considerations and design of customised go-to-market strategies for the implementation of healthcare machine learning detection algorithms.
- Competitor benchmarking of integrated digital patient-facing platforms, and beyond-the pill offerings such as apps and portals, to highlight how pharma companies can achieve non-clinical differentiation through accompanying digital solutions